keyword
MENU ▼
Read by QxMD icon Read
search

Her2 breast cancer

keyword
https://www.readbyqxmd.com/read/28550498/expression-of-calretinin-in-high-grade-hormone-receptor-negative-invasive-breast-carcinomas-correlation-with-histological-and-molecular-subtypes
#1
Donata Micello, Alberto Bossi, Alessandro Marando, Emanuele Dainese, Fausto Sessa, Carlo Capella
Calretinin expression has been reported in neoplasms arising in various organs, including the breast. We investigated the relationship of calretinin expression with different histological and molecular subtypes of invasive breast carcinomas (IBCs) and its prognostic significance in high-grade female hormone receptor-negative IBCs. A total of 196 cases of IBCs of different histological subtypes were analyzed for immunohistochemical expression of calretinin, human epidermal growth factor receptor 2 (HER2), basal-like (BL), apocrine, and proliferative markers and grouped in different molecular subtypes...
May 26, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28550385/metastatic-breast-carcinoma-to-the-superior-oblique-in-a-male
#2
Yao Wang, Pradeep Mettu, Amanda Maltry, Andrew Harrison, Ali Mokhtarzadeh
We describe a case of breast cancer metastatic to the superior oblique, in a male. The patient was a 66-year-old Caucasian male with a history of stage IIIB rectal adenocarcinoma and stage IIA left breast carcinoma diagnosed 12 years and 5 years prior, respectively, who presented with headaches and intermittent diplopia. He underwent left total mastectomy with sentinel lymph node biopsy 6 years prior, which showed ER/PR+, HER2/neu-, moderately-differentiated, infiltrating ductal carcinoma with 3/14 positive nodes...
May 26, 2017: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/28549309/switching-between-intravenous-and-subcutaneous-trastuzumab-safety-results-from-the-prefher-trial
#3
Joseph Gligorov, Giuseppe Curigliano, Volkmar Müller, Ann Knoop, Valerie Jenkins, Sunil Verma, Stuart Osborne, Sabine Lauer, Zuzana Machackova, Lesley Fallowfield, Xavier Pivot
AIM: To assess the safety and tolerability of switching between subcutaneous (SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166). PATIENTS AND METHODS: Patients with HER2-positive early breast cancer completed (neo)adjuvant chemotherapy and were randomised to receive four cycles of SC trastuzumab, via single-use injection device (SID; Cohort 1) or hand-held syringe (Cohort 2), followed by four cycles of IV, or vice versa (the crossover period presented here) as part of their 18 standard cycles of adjuvant trastuzumab treatment...
May 23, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28549033/estrogen-receptor-progesterone-receptor-and-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-assessing-the-value-of-repeated-centralized-testing-in-excision-specimens
#4
Nosaibah Hariri, Farnaz Hasteh, Vighnesh Walavalkar, Andres A Roma, Oluwole Fadare
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2...
May 25, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28549010/a-clinical-feasibility-trial-for-identification-of-exceptional-responders-in-whom-breast-cancer-surgery-can-be-eliminated-following-neoadjuvant-systemic-therapy
#5
Henry M Kuerer, Gaiane M Rauch, Savitri Krishnamurthy, Beatriz E Adrada, Abigail S Caudle, Sarah M DeSnyder, Dalliah M Black, Lumarie Santiago, Brian P Hobbs, Anthony Lucci, Michael Gilcrease, Rosa F Hwang, Rosalind P Candelaria, Mariana Chavez-MacGregor, Benjamin D Smith, Elsa Arribas, Tanya Moseley, Mediget Teshome, Makesha V Miggins, Vicente Valero, Kelly K Hunt, Wei T Yang
OBJECTIVE: To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted core biopsy (VACB) in assessing the presence of residual cancer in the breast after neoadjuvant systemic therapy (NST). SUMMARY BACKGROUND DATA: Pathologic complete response (pCR) rates after NST have improved dramatically, suggesting that surgery might be avoided in some patients. Safe avoidance of surgery would require accurate confirmation of no residual invasive/in situ carcinoma...
May 25, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28548467/outcomes-of-trastuzumab-therapy-for-6-and-12-months-in-indonesian-national-health-insurance-system-clients-with-operable-her2-positive-breast-cancer
#6
Wirsma Arif Harahap, Ramadhan, Daan Khambri, Samuel Haryono, Ricvan Dana Nindrea
Objective: The aim of this study is to determine the outcome of trastuzumab therapy for 6 or 12 months in patients with HER2 positive operable breast cancer who followed the national health insurance system in Indonesia. Methods: Data were extracted from medical records of Dr. M Djamil General Hospital Padang and Dharmais Cancer Hospital/ National Cancer Center Jakarta for post-operative breast HER-2 positive cancer patients treated with trastuzumab for 6 or 12 months who had been followed up for at least 5 years (January 1st in 2010 until December 31st in 2015)...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28548129/central-pathology-review-with-two-stage-quality-assurance-for-pathological-response-after-neoadjuvant-chemotherapy-in-the-artemis-trial
#7
Jeremy St John Thomas, Elena Provenzano, Louise Hiller, Janet Dunn, Clare Blenkinsop, Louise Grybowicz, Anne-Laure Vallier, Ioannis Gounaris, Jean Abraham, Luke Hughes-Davies, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, Carlos Caldas, John Ms Bartlett, David Allan Cameron, Richard Laurence Hayward, Helena Margaret Earl
The ARTemis Trial tested standard neoadjuvant chemotherapy±bevacizumab in the treatment of HER2-negative early breast cancer. We compare data from central pathology review with report review and also the reporting behavior of the two central pathologists. Eight hundred women with HER2-negative early invasive breast cancer were recruited. Response to chemotherapy was assessed from local pathology reports for pathological complete response in breast and axillary lymph nodes. Sections from the original core biopsy and surgical excision were centrally reviewed by one of two trial pathologists blinded to the local pathology reports...
May 26, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28548128/genomic-profiling-of-breast-secretory-carcinomas-reveals-distinct-genetics-from-other-breast-cancers-and-similarity-to-mammary-analog-secretory-carcinomas
#8
Gregor Krings, Nancy M Joseph, Gregory R Bean, David Solomon, Courtney Onodera, Eric Talevich, Iwei Yeh, James P Grenert, Elizabeth Hosfield, Emily D Crawford, Richard C Jordan, Annemieke van Zante, Charles Zaloudek, Sandra J Shin, Yunn-Yi Chen
Secretory carcinomas of the breast are rare tumors with distinct histologic features, recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion and indolent clinical behavior. Mammary analog secretory carcinomas arising in other sites are histopathologically similar to the breast tumors and also harbor ETV6-NTRK3 fusions. Breast secretory carcinomas are often triple (estrogen and progesterone receptor, HER2) negative with a basal-like immunophenotype. However, genomic studies are lacking, and whether these tumors share genetic features with other basal and/or triple negative breast cancers is unknown...
May 26, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28547977/the-association-of-tumor-lymphocyte-infiltration-with-clinicopathological-factors-and-survival-in-breast-cancer
#9
Joanna Huszno, Ewa Zembala Nożyńska, Dariusz Lange, Zofia Kołosza, Elżbieta Nowara
Recent studies have confirmed the role of tumor-infiltrating lymphocytes (TILs) in carcinogenesis and cancer progression. The aim of this study was to evaluate the correlation between the level of tumor lymphocyte infiltration and well-known clinicopathological factors in breast cancer patients. We also evaluated the influence of TILs on overall survival. Paraffin sections were retrospectively evaluated in 76 cases in early stage breast cancer patients who underwent surgery followed by systemic treatment. Tumor-infiltrating lymphocytes were classified as absent (grade 0), mild (grade 1), moderate (grade 2), or severe (grade 3)...
2017: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/28547976/prevalence-of-biological-types-of-breast-cancer-and-their-influence-on-disease-staging-and-therapeutic-management-a-single-center-study
#10
Tomasz Nowikiewicz, Ewa Chmielowska, Hanna Andrusewicz, Joanna Łysik-Miśkurka, Iwona Głowacka, Magdalena Sowa, Wojciech Zegarski
According to the St. Gallen 2011 consensus, proper qualification of breast cancer patients for treatment requires taking into consideration the division into biological types of neoplasms. The goal of this work was to assess the prevalence of all biological types of breast cancer in the population of Kuyavian-Pomeranian province. We determined the influence of particular types of neoplasms on the degree of disease progression and the choice of therapeutic management. The study was conducted on a group of 2653 patients treated surgically due to malignant breast tumors in the Oncology Centre in Bydgoszcz...
2017: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/28547525/neoadjuvant-chemotherapy-with-trastuzumab-docetaxel-and-carboplatin-administered-every-3%C3%A2-weeks-for-japanese-women-with-her2-positive-primary-breast-cancer-efficacy-and-safety
#11
Ikuko Sugitani, Shigeto Ueda, Takashi Sakurai, Takashi Shigekawa, Eiko Hirokawa, Hiroko Shimada, Hideki Takeuchi, Kazuo Matsuura, Misono Misumi, Nobuko Fujiuchi, Takao Takahashi, Takahiro Hasebe, Akihiko Osaki, Toshiaki Saeki
BACKGROUND: This phase II neoadjuvant study evaluated the efficacy and safety of a triweekly regimen of docetaxel and carboplatin in combination with trastuzumab (TCbH) in Japanese women with human epidermal growth factor receptor type2 (HER2)-positive primary breast cancer. METHODS: Patients with HER2-positive, stage I-III invasive breast cancer received six courses of trastuzumab (8 mg/kg loading dose, then 6 mg/kg, day 1), docetaxel (75 mg/m(2), day 1), and carboplatin (area under the curve: 6, day 1) every 3 weeks...
May 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28545563/additional-value-of-18-f-fdg-pet-ct-response-evaluation-in-axillary-nodes-during-neoadjuvant-therapy-for-triple-negative-and-her2-positive-breast-cancer
#12
Mette S van Ramshorst, Suzana C Teixeira, Bas B Koolen, Kenneth E Pengel, Kenneth G Gilhuijs, Jelle Wesseling, Sjoerd Rodenhuis, Renato A Valdés Olmos, Emiel J Rutgers, Wouter V Vogel, Gabe S Sonke, Marie-Jeanne T Vrancken Peeters
BACKGROUND: (18)F-FDG PET/CT can monitor metabolic activity in early breast cancer during neoadjuvant systemic therapy (NST), but it is unknown if the metabolic breast and axillary response differ. We evaluated the correlation between metabolic breast and axillary response at various time points during NST. Furthermore, we analysed if the combined metabolic response improves pathologic complete response (pCR) prediction compared to using the metabolic breast response alone. METHODS: (18)F-FDG PET/CT was performed at baseline (PET1), 2-3 weeks (PET2), and 6-8 weeks (PET3) of NST in patients with triple-negative (TN) and HER2-positive node-positive breast cancer...
May 25, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/28545469/age-related-terminal-duct-lobular-unit-involution-in-benign-tissues-from-chinese-breast-cancer-patients-with-luminal-and-triple-negative-tumors
#13
Changyuan Guo, Hyuna Sung, Shan Zheng, Jennifer Guida, Erni Li, Jing Li, Nan Hu, Joseph Deng, Jonine D Figueroa, Mark E Sherman, Gretchen L Gierach, Ning Lu, Xiaohong R Yang
BACKGROUND: Terminal duct lobular unit (TDLU) involution is a physiological process of breast tissue aging characterized by a reduction in the epithelial component. In studies of women with benign breast disease, researchers have found that age-matched women with lower levels of TDLU involution are at increased risk of developing breast cancer. We previously showed that breast cancer cases with core basal phenotype (CBP; estrogen receptor negative [ER(-)], progesterone receptor-negative [PR(-)], human epidermal growth factor receptor 2-negative [HER2(-)], cytokeratins (CK 5 or CK5/6)-positive [CK5/6(+)] and/or epidermal growth factor receptor-positive [EGFR(+)]) tumors had significantly reduced TDLU involution compared with cases with luminal A (ER(+) and/or PR(+), HER2(-), CK5/6(-), EGFR(-)) tumors from a population-based case-control study in Poland...
May 25, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28544923/unfavorable-prognostic-role-of-tumor-infiltrating-lymphocytes-in-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-treated-with-metronomic-chemotherapy
#14
Emilia Montagna, Andrea Vingiani, Patrick Maisonneuve, Giuseppe Cancello, Federica Contaldo, Giancarlo Pruneri, Marco Colleoni
BACKGROUND: High levels of tumor-infiltrating lymphocytes (TILs) in primary triple negative and HER2-positive breast cancer (BC) have been associated with an improved patients' outcome. The role of TILs in Luminal (hormone receptor positive and HER2 negative) tumors remains to be elucidated. Moreover, the association between TILs and prognosis in the metastatic setting is still unknown. PATIENTS AND METHODS: We evaluated the relationship between TILs and time to progression (TTP) in metastatic BC patients enrolled in a prospective phase II trial of metronomic chemotherapy, that used cyclophosphamide 50 mg daily, capecitabine 500 mg thrice daily and vinorelbine 40 mg orally three times a week (VEX combination)...
May 22, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28540335/ny-eso-1-expression-in-dcis-a-new-predictor-of-good-prognosis
#15
R Charles Coombes, Otavia L Caballero, Sami Shousha, Sadaf Ghaem-Maghami, Laura Woodley-Barker, Charlotte S Wilhelm-Benartzi, A Munro Neville
BACKGROUND: At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC. RESULTS: 14 of 42 (33%) of patients developed invasive breast cancer during the follow up period...
March 2017: Oncoscience
https://www.readbyqxmd.com/read/28539475/the-brain-microenvironment-mediates-resistance-in-luminal-breast-cancer-to-pi3k-inhibition-through-her3-activation
#16
David P Kodack, Vasileios Askoxylakis, Gino B Ferraro, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Z Alexander Cao, Rakesh R Ramjiawan, Divya Bezwada, Bhushankumar Patel, Yongchul Song, Carlotta Costa, Kamila Naxerova, Christina S F Wong, Jonas Kloepper, Rita Das, Angela Tam, Jantima Tanboon, Dan G Duda, C Ryan Miller, Marni B Siegel, Carey K Anders, Melinda Sanders, Monica V Estrada, Robert Schlegel, Carlos L Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A Engelman, Rakesh K Jain
Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed that brain metastases evade phosphatidylinositide 3-kinase (PI3K) inhibition despite drug accumulation in the brain lesions. In comparison to extracranial disease, we observed increased HER3 expression and phosphorylation in brain lesions. HER3 blockade overcame the resistance of HER2-amplified and/or PIK3CA-mutant breast cancer brain metastases to PI3K inhibitors, resulting in marked tumor growth delay and improvement in mouse survival...
May 24, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28537889/immune-signature-of-metastatic-breast-cancer-identifying-predictive-markers-of-immunotherapy-response
#17
Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, Woong-Yang Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
In breast cancer (BC), up to 10-20% patients were known to have clinical benefit with immune checkpoint inhibitors, and biomarkers are needed for optimal use of this multi-potential therapeutic strategy. Accordingly, we conducted an experiment to identify expression of genes associated with immune checkpoints that represent potential targets of cancer immunotherapy. We performed whole-transcriptome sequencing and whole-exome sequencing using 37 refractory BC specimens. In the immune pathway gene set expression analysis, we found that HER2 expression and previous taxane treatment were positively correlated with high expression of immune gene set expression (p = 0...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28535656/-the-role-of-supraclavicular-lymph-node-dissection-in-breast-cancer-patients-with-synchronous-ipsilateral-supraclavicular-lymph-node-metastasis
#18
W Zhang, X M Qi, A X Chen, P Zhang, X C Cao, C H Xiao
Objective: In this study, we evaluated the effect of supraclavicular lymph node dissection in breast cancer patients who presented with ipsilateral supraclavicular lymph node metastasis (ISLM) without distant metastasis. Methods: A total of 90 patients with synchronous ISLM without distant metastasis between 2000 and 2009 were retrospectively analyzed. Patients were retrospectively divided into two groups, namely supraclavicular lymph node dissection group(34 patients) and non-dissection group(56 patients), according to whether they underwentsupraclavicular lymph node dissection or not...
May 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28534358/prognostic-implications-of-the-intrinsic-molecular-subtypes-in-male-breast-cancer
#19
Abdeljaoued Syrine, Bettaieb Lhem, Nasri Meher, Adouni Olfa, Goucha Aida, Bouzaiene Hatem, Boussen Hamouda, Rahal Khaled, Gamoudi Amor
PURPOSE: Intrinsic molecular subtyping has been widely used in female breast cancer, and it has proven its significance. In this article, we aimed to study the intrinsic subtypes of male breast cancer (MBC) in correlation with clinicopathological features. METHODS: We retrospectively identified 130 MBC cases from 2004 to 2013. Intrinsic molecular subtypes were determined by immunohistochemistry (IHC). RESULTS: From a total of 130 MBC cases, 45...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28534357/comparative-study-of-receptor-discordance-between-primary-and-corresponding-metastatic-lesions-in-breast-cancer
#20
Gokmen U Erdem, Kadri Altundag, Nuriye Y Ozdemir, Suleyman Sahin, Nebi S Demirci, Fatih Karatas, Yakup Bozkaya, Aydin Aytekin, Vildan Tasdemir, Alma C Aslan, Ali R Sever, Nurullah Zengin
PURPOSE: It is well-known that tumor phenotype may change during the progression of breast cancer (BC). The purpose in this study was to compare the discordance in estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) between primary and recurrent/metastatic lesions (RML) and also to evaluate the prognostic significance of change in tumor phenotype on survival in patients with metastatic BC. METHODS: The medical records of 6638 patients with BC from two breast centers treated between 1992 and 2015 were retrospectively analyzed...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
keyword
keyword
5319
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"